The estimated Net Worth of Rahul Kakkar is at least $841 Тысяча dollars as of 17 July 2020. Rahul Kakkar owns over 14,000 units of Pandion Therapeutics stock worth over $840,700 and over the last 4 years Rahul sold PAND stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Rahul Kakkar PAND stock SEC Form 4 insiders trading
Rahul has made over 1 trades of the Pandion Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Rahul bought 14,000 units of PAND stock worth $252,000 on 17 July 2020.
The largest trade Rahul's ever made was buying 14,000 units of Pandion Therapeutics stock on 17 July 2020 worth over $252,000. On average, Rahul trades about 4,667 units every 0 days since 2020. As of 17 July 2020 Rahul still owns at least 14,000 units of Pandion Therapeutics stock.
You can see the complete history of Rahul Kakkar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Rahul Kakkar's mailing address?
Rahul's mailing address filed with the SEC is C/O PANDION THERAPEUTICS, INC., 134 COOLIDGE AVENUE, WATERTOWN, MA, 02472.
Insiders trading at Pandion Therapeutics
Over the last 4 years, insiders at Pandion Therapeutics have traded over $0 worth of Pandion Therapeutics stock and bought 1,743,632 units worth $30,815,954 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Kol... и Daniel J. Becker. On average, Pandion Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $9,518,646. The most recent stock trade was executed by Daniel J. Becker on 19 November 2020, trading 197,716 units of PAND stock currently worth $2,989,466.
What does Pandion Therapeutics's logo look like?
Complete history of Rahul Kakkar stock trades at Pandion Therapeutics
Pandion Therapeutics executives and stock owners
Pandion Therapeutics executives and other stock owners filed with the SEC include:
-
Capital Management, L.P.Kol...,
-
Nancy Stagliano,
Director -
Vikas Goyal,
See Remarks -
Joanne L. Viney,
See Remarks -
Partners Gp Viii, L.L.C.Pol...,
-
Rizzuto Carlo,
Director -
Jill Carroll,
Director -
Katina Dorton,
Director -
Donald Frail,
Director -
Christopher Fuglesang,
Director -
Gregg Beloff,
See Remarks -
Alan L Crane,
Director -
Mitchell Mutz,
Director -
Eric D Larson,
Vice President, Finance -
Daniel J. Becker,
Director -
Rahul Kakkar,
Chief Executive Officer -
Plc Gsk,
Director -
John Sundy,
Chief Medical Officer -
Edward D. Freedman,
Chief Operating Officer